Thermo Fisher Scientific has put forward a DNA-based test it says can offer much more precise identification of blood and its ...

Johnson & Johnson is shelling out $850 million to buy Proteologix, getting hold of a young roster of bispecific immunology ...

Biogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the drugmaker’s early-stage pipeline ...

After picking up $100 million in venture capital cash earlier this month, Karius is adding another feather to its cap with a ...

Eli Lilly finds itself in a familiar position: snapping at the heels of Novo Nordisk. The Indianapolis-based drugmaker kept ...

Health has gathered $25 million in funding to help continue clinical studies of its less invasive, outpatient procedure for ...

The FDA has approved two diagnostic devices that allow women to collect vaginal samples themselves for cervical cancer ...

Results from the phase 3 SUPERNOVA study show that the company’s investigational long-acting antibody (LAA) sipavibart produced a statistically significant reduction in the incidence of symptomatic ...

What a time to be launching a new biotech focused on inflammation and immunology. | Immunology and inflammation-focused drug ...

BioMarin had already announced plans to cut its pipeline in half, but now the company has confirmed that 170 employees are ...

Vaxxinity, which filed to delist from the Nasdaq last month, is choosing radical transparency about the “abusive relationship ...

The FDA is recommending that if anyone still has any home COVID tests left from Cue Health, they should throw them away.  | ...